Medicina em Foco · MEDICAL ARTICLE
Bariatric surgery still has a role and may cost less than weight-loss injections in the long term
An honest comparison of surgery and injectable medication: who each approach is for, what each demands of your body and budget, and when they work together.
Dr. Rodrigo BarbosaCRM-SP 167670 · RQE 78610 · RQE 151325

In this article
- Why do we hear so much about injections and so little about surgery today?
- When does excess weight call for more than diet and exercise?
- Who is a candidate for surgery, and who is a candidate for medication?
- What can you expect from each approach, and what are the risks?
- What happens when the injections are stopped?
- How much does each approach cost over 1, 3, and 5 years?
- When do the two approaches complement each other, and when is medication the more appropriate choice?
- How it works at Instituto Medicina em Foco
- What happens after the decision?


Why do we hear so much about injections and so little about surgery today?
Injections have become an everyday topic, but that does not mean surgery has lost its place.
If you live with excess weight, you have probably heard someone say they started using weight-loss injections. Injectable medications for obesity have gained ground quickly, and for good reason: they are a real medical achievement.
Two of them are semaglutide and tirzepatide, recently approved for weight management in adults. They act on areas of the brain that control appetite, reducing hunger, and slow stomach emptying.
What almost never comes up in the same conversation is the long-term comparison. Treating obesity is not a project lasting a few months. Obesity is a chronic disease, and studies indicate that treatment needs to continue to maintain weight and health. So the right question is not just which approach leads to weight loss, but which one you can maintain for five, ten, or twenty years.
This article is not intended to criticize medication or push anyone into the operating room. It is meant to help you arrive at your consultation knowing what to ask. To understand the disease itself, we have a page about obesity as a chronic disease, with causes, risks, and treatments.
When does excess weight call for more than diet and exercise?
Some signs suggest it is worth seeking medical evaluation for treatment beyond changes in habits.
Diet and physical activity are the foundation of any treatment, with medication or surgery. But for many people, they are not enough on their own, and that is not a lack of willpower. After weight loss, the body often reaches a plateau and gradually regains weight. Biological, behavioral, and environmental factors push in that direction.
It is worth talking with a doctor about obesity treatment when:
Who is a candidate for surgery, and who is a candidate for medication?
Each approach has defined criteria, and they are not the same.
In general, surgery is considered for people with a BMI (body mass index) of 40 or higher, or 35 or higher with serious obesity-related diseases. There is also growing evidence supporting consideration of surgery in people with type 2 diabetes and a BMI between 30 and 35 whose blood glucose remains poorly controlled despite appropriate medical treatment.
If you have a health plan, it is worth checking in advance which rules and documents it requires to cover surgery. The indication must meet medical criteria and be well documented.
Medication is recommended for adults with a BMI (body mass index) of 30 or higher, or 27 or higher with a weight-related complication, when changes in habits alone have not produced sufficient results, and always alongside those changes. This means many people who can use medication are not candidates for surgery, and many who are candidates for surgery could, in principle, also use medication. This overlap is where the decision becomes difficult and needs to be individualized.
The doctor assesses the indication by looking at your complete history. A conversation with a gastrointestinal surgeon, together with an endocrinologist, dietitian, and psychologist, helps you see both sides before choosing.
What can you expect from each approach, and what are the risks?
Both treatments work, but the size of the result and the type of risk differ.
In the large semaglutide study, average weight loss was 14,9% in 68 weeks, compared with 2,4% in the placebo group. For surgery, the Swedish SOS study followed patients for 10 to 20 years: average weight loss was 23% after 2 years and still 18% after 20 years.
Surgery has risks, and it is fair to discuss them clearly. Today, the risk of death related to the operation is between 0,03% and 0,2%, much lower than in the early 2000s. Soon after surgery, there may be leakage along the staple or suture line (called a fistula), narrowing, and bleeding.
In the long term, guidelines recommend checking and, when needed, replacing vitamins and minerals such as iron, vitamin B12, calcium, and vitamin D, as well as taking supplements to prevent deficiencies. After gastric bypass, some people develop heartburn and reflux, dumping syndrome, or bowel obstruction. Over time, sleeve gastrectomy can cause reflux, and bypass can cause ulcers and internal hernias.
Medication also has effects that deserve attention. With semaglutide, the most common in the large study were nausea and diarrhea, generally mild to moderate, temporary, and decreasing over time. In semaglutide studies in adults with obesity without diabetes, serious events mainly involved the digestive system and gallbladder, such as acute pancreatitis and gallstones. Injections lead to fat loss, and most studies also showed loss of lean mass, more pronounced with longer treatment.
What is reassuring: bariatric surgery complications are sometimes serious, but uncommon. And with semaglutide, the most common effects tended to resolve over time, as described above.

What happens when the injections are stopped?
Evidence shows that when medication is stopped, most of the weight tends to return.
This is the question that matters most in the long-term calculation. Injections control hunger while the medication is in the body. When stopped, the effect goes away.
In the study that followed people for one year after stopping semaglutide and the lifestyle program, about two-thirds of the lost weight returned. In another study, people who switched from tirzepatide to placebo regained much of the weight they had lost, while those who continued the medication maintained and increased their results. Along with the weight, most improvements in cardiovascular and metabolic risk factors returned close to their previous levels.
This does not mean the medication failed. It means it works as an ongoing treatment. In practice, deciding to start injections also means deciding to continue them indefinitely, or having a clear plan with your doctor for when the dose is reduced.
Surgery does not protect against everything either: some people regain a significant amount of weight over the years. But the change made to the stomach and intestine remains, without depending on a weekly injection.
How much does each approach cost over 1, 3, and 5 years?
Injections are a recurring monthly expense; surgery concentrates the cost at the beginning.
Prices change over time and with the dose. The table below shows the calculation with its source and date, followed by the reasoning, which does not change.
| Self-pay bariatric surgery | Tirzepatide 5 mg per week | Tirzepatide 10 mg per week | Tirzepatide 15 mg per week | |
|---|---|---|---|---|
| Over 1 year | R$ 22,980.00 (≈ US$ 4010, estimated), paid once Estimated value in US dollars at the tourist exchange rate, updated daily; payment is made in Brazilian reais. | R$ 29,589.00 (≈ US$ 5163, estimated) | R$ 41,918.00 (≈ US$ 7314, estimated) | R$ 54,247.00 (≈ US$ 9465, estimated) |
| Over 3 years | R$ 22,980.00 (≈ US$ 4010, estimated), paid once | R$ 88,768.00 (≈ US$ 15487, estimated) | R$ 125,754.00 (≈ US$ 21940, estimated) | R$ 162,741.00 (≈ US$ 28393, estimated) |
| Over 5 years | R$ 22,980.00 (≈ US$ 4010, estimated), paid once | R$ 147,946.00 (≈ US$ 25812, estimated) | R$ 209,589.00 (≈ US$ 36567, estimated) | R$ 271,235.00 (≈ US$ 47322, estimated) |
| When spending on injections exceeds the cost of surgery | — | Around month 10 | Around month 7 | Around month 5 |
Injection pen: Maximum Consumer Price (PMC) with 18% ICMS state tax (São Paulo) from the CMED/Anvisa (Brazil's drug pricing authority/health regulatory agency) list published on November 9, 2026, multidose tirzepatide pen with 4 weekly doses (13 pens per year), at the indicated maintenance dose; does not include the initial dose-escalation phase, consultations, or tests. Pharmacies may sell below the PMC. Surgery: upfront package price at Hospital IGESP published on drrodrigobarbosa.com.br, checked on November 15, 2026; other hospitals have different prices. The package excludes the consultation (R$ 800.00 (≈ US$ 140, estimated)), preoperative tests, ongoing vitamins, and follow-up. Reference prices, without adjustments; not a quote.
With medication, the expense is monthly and adds up. In the first year, it already amounts to a considerable sum. Over three years, that sum triples, and over five years it may exceed the cost of self-pay surgery. Because the dose is increased gradually in the first few months, the monthly expense may also rise during that period. It is worth checking whether your health plan covers the injections.
With self-pay surgery, almost the entire cost comes at once, usually as a package. But it is important to ask what is excluded. Items commonly excluded or charged separately include preoperative evaluation tests, dietitian and psychologist consultations, complications requiring a longer hospital stay, ongoing vitamins, regular follow-up tests, and, for some people, plastic surgery to remove excess skin.
Through a health plan, surgery coverage depends on the plan's rules and whether the indication meets the criteria. Ask the plan about waiting periods and, if obesity was disclosed when signing up, temporary partial coverage. Even with coverage, some items may be paid separately, depending on the contract. So be wary of any promise of fully covered surgery without reviewing your plan.
Money should not decide on its own. But when both options make sense for your case, putting the five-year costs on paper helps you make a realistic decision.
When do the two approaches complement each other, and when is medication the more appropriate choice?
Surgery and injections are not rivals: in many cases, one helps the other.
Medicine already uses both together in several situations. The choice does not have to be one or the other forever.
How it works at Instituto Medicina em Foco
The first step is an evaluation to understand your case, without a decision made in advance.
The starting point is an evaluation consultation. During it, the doctor discusses your weight history, treatments you have tried, associated diseases, and what you expect from treatment.
From there, the doctor explains whether you meet the criteria for surgery, medication, or both, and which tests would be needed. If you have a health plan, the team helps check what it covers, waiting periods, and what may need to be paid separately.
You leave the consultation with the options explained and time to think. No decision needs to be made that same day.
What happens after the decision?
Whichever approach you choose, treatment continues with follow-up.
If medication is chosen, follow-up includes gradual dose adjustment, management of side effects, and guidance on diet and physical activity. With injections, lean mass loss was more evident in those who used the medication longer.
If surgery is chosen, a preparation phase follows with tests and nutrition and psychology evaluations. After the operation, follow-up with the team continues. With this care, the team helps maintain long-term weight loss and reduce the risk of nutritional problems, both soon afterward and over the years.
Treating obesity means caring for your health over a long time, and that care can start with a conversation.
Bariatric surgery × maintenance injectable medication
| Bariatric surgery | Injectable medication | |
|---|---|---|
| Who it is for | BMI (body mass index) 40+, or 35+ with serious obesity-related diseases | BMI (body mass index) 30+, or 27+ with a weight-related complication, when changes in habits were not enough |
| Expected weight loss | In the SOS study, an average of 23% of body weight after 2 years and 18% after 20 years | With tirzepatide, an average of 15,0% to 20,9% of body weight in 72 weeks, while taking it |
| Main risks | Fistula, narrowing, and bleeding soon after the operation | With semaglutide: nausea and diarrhea, generally mild to moderate and temporary |
| When stopped or over time | Some people regain weight over the years | Stopping tirzepatide led to significant regain of lost weight |
| Cost structure | Concentrated at the beginning, plus vitamins and follow-up tests | Monthly and ongoing; adds up with each year of use |
| Health plan | Depends on the plan and eligibility criteria; waiting periods may apply | Check your contract |
Outcome data: STEP 1 and its extension (semaglutide), SURMOUNT-1 and SURMOUNT-4 (tirzepatide), and the Swedish SOS study (bariatric surgery); indication criteria from a review published in JAMA (2020) and the AGA guideline (2022), accessed in November 2026. The comparison considers adults with obesity and excludes other treatments, such as a gastric balloon, and adolescent cases. Drawbacks of surgery include procedural risks, recovery time, vitamin and mineral monitoring, and costs outside the package. Drawbacks of medication include ongoing costs and weight regain after stopping. Prices in reais are in the table in the cost section, with source and date.
Frequently asked questions
Do weight-loss injections replace bariatric surgery?
For adults with overweight or obesity who have not achieved sufficient results through changes in habits alone, injections are a long-term treatment option. In severe obesity, surgery usually leads to greater weight loss than nonsurgical treatments. The doctor determines the approach based on an evaluation of your case.
If I stop the injections, will I regain the weight?
In the semaglutide study, people regained about two-thirds of the weight they had lost one year after stopping the medication and the lifestyle program. That is why stopping or reducing the dose should be planned with your doctor.
Is bariatric surgery dangerous?
Every surgery has risks. With bariatric surgery, complications are sometimes serious, but they are uncommon. In the long term, an important concern is vitamin and mineral deficiency, which is expected after the operation and needs monitoring.
Does my health plan cover bariatric surgery?
It depends on the plan and whether you meet the criteria. Also ask about waiting periods and temporary partial coverage. The team reviews your contract with you.
Does my health plan pay for the injections?
That depends on the contract. Some contracts or specific programs may have different rules; it is worth checking with your plan.
Can I use the injections after surgery?
Yes. In cases of weight regain or less weight loss than expected, medication may be used after surgery with a doctor's recommendation and follow-up.
How long does recovery from surgery take?
Recovery time and the return to a normal diet depend on the technique and the individual. The surgeon explains each stage during the consultation.
Do I need to bring any test results to the consultation?
It is not required. If you have recent blood or imaging tests, or a list of medications you have used to lose weight, bring them: they help the doctor understand your history.
References
- Arterburn DE et al. Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022.
- Safwan M et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025.
- Moiz A et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025.
- Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am. 2018.
- Grunvald E et al.; American Gastroenterological Association. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022.
- Tan HC et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022.
- Wilding JPH et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
- Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013.
- Contival N et al. Guiding the non-bariatric surgeon through complications of bariatric surgery. J Visc Surg. 2018.
- Parrott J et al. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017.
- Moizé V et al. Nutritional Challenges and Treatment After Bariatric Surgery. Annu Rev Nutr. 2024.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- Noria SF et al. Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment. Curr Diab Rep. 2023.
- Esparham A et al. Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review. Obes Surg. 2025.
- Esparham A et al. Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis. Obes Rev. 2024.
- Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Lu J et al. The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials. Eur J Pharmacol. 2025.
Where we see patients
Rua Frei Caneca, 1380, térreo (Edifício Crystal Tower), Consolação, São Paulo-SP, CEP 01307-000, Brasil
Book via WhatsAppRead also
Informational content. Does not replace a medical consultation.
Updated on